Web Exclusives
CLL Monthly MinutesLeukemia
COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals.
CLL Monthly MinutesLeukemia
Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas.
By Carol Bustos
Sharing your cancer story can promote your sense of what’s truly important, giving you hope and strength in difficult times.
Genomic/Genetic TestingCholangiocarcinoma
By Jim Palma, John Hopper
Jim Palma and John Hopper, Co-Chairs of NORD Rare Cancer Coalition, explain the difference between genetic testing and genomic profile testing, and why all patients with rare cancers should have a genomic profile done to select the best treatment for them based on potential genomic alteration.
CLL Monthly MinutesLeukemia
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.
CLL Monthly MinutesLeukemia
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
CLL Monthly MinutesLeukemia
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.
CLL Monthly MinutesLeukemia
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia.
CLL Monthly MinutesLeukemia
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end.
